Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Tuning Immune T cells for cancer therapy

Project description

Immune platform for improved adoptive cell therapy

Adoptive cell therapy (ACT) is a type of immunotherapy using mainly donor-derived cells which are modified and expanded outside the body, and then reinfused into the patient to help fight diseases like cancer. The most well-known ACT is chimeric antigen receptor-T cell therapy which exhibits T cell exhaustion issues during ex vivo expansion, leading to dysfunctional T cells. To overcome this problem, the ERC-funded Tune-IT project will develop an artificial antigen-presenting cell platform to enhance T cell expansion efficiently. Researchers will validate the platform’s ability to maintain T cell function, improve patient outcomes and assess commercial viability.

Objective

Adoptive cell therapy (ACT) recently became an important treatment modality for cancer . Since 2017, several chimeric antigen receptor (CAR)-T cell therapies approved by the FDA/EMA and more are expected to receive approval for clinical use. Currently, more than 250 clinical ACT trials are ongoing. Already in 2021, the market size was >$1 billion and is expected to grow tremendously to >$25 billion by 2030. ACT products require extensive ex vivo manipulation and expansion of patient derived T cells prior to reinfusion back into patients to attack cancer cells. Unfortunately, T cell exhaustion and loss of function after reinfusion form a major problem in currently used ex vivo expansion protocols.

The solution.
Dedicated tuning of T cells during ex vivo expansion to preserve their anti- cancer function and prevent exhaustion. In the body, T cells are activated by antigen presenting cells (APC) to initiate an immune response. As patient-derived APC are often immunosuppressed, much effort is spent on developing 'artificial antigen presenting cells' (aAPC) to expand immune cells for ACT. We developed a unique polymeric aAPC platform, termed immunofilaments, that provide a highly flexible-, scalable-, GMP compliant- and affordable- solution for robust production of T cells for ACT. Our initial findings indeed indicate that we can diminish T cell exhaustion and outcompete products currently used in the clinic for ex vivo T cell expansion.

Tune-IT will validate the technical and commercial feasibility of this novel technology platform that exploits immunofilaments to significantly improve function and longevity of ACT products in patients.
In Tune-IT, we will: 1) demonstrate that tuning of ex vivo cultured therapeutic T cells will prevent exhaustion and loss of tumor killing capacity after reinfusing T cells and 2) perform market and business case analyses to ensure commercial feasibility and market entry through Simmunext Biotherapeutics, a Radboudumc spin-off

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-POC

See all projects funded under this call

Host institution

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Net EU contribution
€ 150 000,00
Address
GEERT GROOTEPLEIN 10 ZUID
6525 GA Nijmegen
Netherlands
Region
Oost-Nederland Gelderland Arnhem/Nijmegen
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)